Please login to the form below

Not currently logged in
Email:
Password:

Narcolepsy

This page shows the latest Narcolepsy news and features for those working in and with pharma, biotech and healthcare.

Medical Research Council launches disease compounds research library

Medical Research Council launches disease compounds research library

Both pre-clinical and clinical compounds are featured in the MRC library, which includes molecules developed for ADHD, cancer, diabetes and narcolepsy and is the largest resource of its kind.

Latest news

  • Jazz Pharma bags FDA approval for rare disease drug Jazz Pharma bags FDA approval for rare disease drug

    Meanwhile, Jazz already sells two other rare disease therapies - narcolepsy treatment Xyrem (sodium oxybate) and Erwinaze (asparaginase Erwinia chrysanthemi) for acute lymphoblastic leukaemia (ALL) patients who have developed hypersensitivity to

  • Wakix backed for European approval in narcolepsy Wakix backed for European approval in narcolepsy

    Wakix backed for European approval in narcolepsy. Bioprojet Pharma’ s orphan drug given a positive opinion by CHMP. ... Narcolepsy is a rare, long-term sleep disorder, which affects the brain's ability to regulate the normal sleep-wake cycle.

  • Novartis curates interactive history of medicine exhibition Novartis curates interactive history of medicine exhibition

    In pursuit of possible treatments for narcolepsy the Novartis Institutes for BioMedical Research has identified a class of compounds that temporarily blocks a receptor involved with regulating wakefulness - the starting point

  • EU hits Servier and generic firms with €428m 'pay-for-delay' fine EU hits Servier and generic firms with €428m 'pay-for-delay' fine

    Meanwhile, antitrust investigators in the EU are still looking at possible collusion between Teva and Cephalon, which is now owned by the Israeli company, concerning narcolepsy treatment Provigil (modafinil), while a

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    If the acquisition goes through Gentium would be delisted from the Nasdaq and become privately-owned, said Jazz, whose top products are Xyrem (sodium oxybate) for narcolepsy and leukaemia drug

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    490. Aerial BioPharma/ Jazz Pharmaceuticals. Product rights. Jazz gain access to ADX N05 for treatment of narcolepsy, SK Biopharmaceuticals retain some Asian rights, upfront of $125m, Aerial and SK receive milestones

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics